{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:49:13Z","timestamp":1792482553056,"version":"4.5.0"},"reference-count":220,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jfma.2016.11.013","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T22:15:18Z","timestamp":1487974518000},"page":"217-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"title":["2017 Taiwan lipid guidelines for high risk patients"],"prefix":"10.1016","volume":"116","author":[{"given":"Yi-Heng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwo-Chang","family":"Ueng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Shing","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ji","family":"Charng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hsien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Liong","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Hsing","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Yen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Huang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chieh","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Wei","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Chun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Ya","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaw-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau-Chung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-I","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2016.11.013_bib1","doi-asserted-by":"crossref","first-page":"e001066","DOI":"10.1161\/JAHA.114.001066","article-title":"Trends in the incidence and management of acute myocardial infarction from 1999 to 2008: get with the guidelines performance measures in Taiwan","volume":"3","author":"Lee","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jfma.2016.11.013_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijcard.2016.02.022","article-title":"The temporal trends of incidence, treatment, and in-hospital mortality of acute myocardial infarction over 15 years in a Taiwanese population","volume":"209","author":"Yin","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib3","first-page":"238","article-title":"Diet and health trends in Taiwan: comparison of two nutrition and health surveys from 1993\u20131996 and 2005\u20132008","volume":"20","author":"Pan","year":"2011","journal-title":"Asia Pac J Clin Nutr"},{"key":"10.1016\/j.jfma.2016.11.013_bib4","doi-asserted-by":"crossref","first-page":"e0116513","DOI":"10.1371\/journal.pone.0116513","article-title":"Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan","volume":"10","author":"Ho","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2016.11.013_bib5","first-page":"135","article-title":"Clinical characteristics, management and in-hospital outcomes of patients with acute coronary syndrome \u2014 observations from the Taiwan ACS Full Spectrum Registry","volume":"27","author":"Shyu","year":"2011","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.jfma.2016.11.013_bib6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.110.936526","article-title":"Get with the guidelines-stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: get with the guidelines-stroke in Taiwan","volume":"122","author":"Hsieh","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib7","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1161\/CIRCULATIONAHA.113.001470","article-title":"The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008","volume":"127","author":"Danaei","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(10)62038-7","article-title":"National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants","volume":"377","author":"Farzadfar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0021-9150(95)05616-5","article-title":"Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan\u2014a unique experience","volume":"118","author":"Pan","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib10","first-page":"187","article-title":"Prevalence of dyslipidemia and mean blood lipid values in Taiwan: results from the Nutrition and Health Survey in Taiwan (NAHSIT, 1993\u20131996)","volume":"45","author":"Chang","year":"2002","journal-title":"Chin J Physiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00149831-200504000-00003","article-title":"Relative importance of atherosclerotic risk factors for coronary heart disease in Taiwan","volume":"12","author":"Chien","year":"2005","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.jfma.2016.11.013_bib12","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1194\/jlr.M700213-JLR200","article-title":"Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese","volume":"48","author":"Chien","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jfma.2016.11.013_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jfma.2016.11.013_bib14","first-page":"CD003817","article-title":"Exercise for overweight or obesity","volume":"4","author":"Shaw","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfma.2016.11.013_bib15","first-page":"CD009387","article-title":"Exercise for people with high cardiovascular risk","volume":"8","author":"Seron","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfma.2016.11.013_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.mco.0000171152.51034.bf","article-title":"Dietary cholesterol provided by eggs and plasma lipoproteins in healthy populations","volume":"9","author":"Fernandez","year":"2006","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.jfma.2016.11.013_bib17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3945\/ajcn.112.051318","article-title":"Egg consumption in relation to risk of cardiovascular disease and diabetes: a systematic review and meta-analysis","volume":"98","author":"Shin","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jfma.2016.11.013_bib18","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajcn\/77.5.1146","article-title":"Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials","volume":"77","author":"Mensink","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jfma.2016.11.013_bib19","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.ejcn.1602973","article-title":"Health effects of trans-fatty acids: experimental and observational evidence","volume":"63","author":"Mozaffarian","year":"2009","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jfma.2016.11.013_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/69.1.30","article-title":"Cholesterol-lowering effects of dietary fiber: a meta-analysis","volume":"69","author":"Brown","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jfma.2016.11.013_bib21","series-title":"2015\u20132020 dietary guidelines for Americans","author":"U.S. Department of Health and Human Services","year":"2015"},{"key":"10.1016\/j.jfma.2016.11.013_bib22","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM198811033191801","article-title":"Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise","volume":"319","author":"Wood","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib23","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa020194","article-title":"Effects of the amount and intensity of exercise on plasma lipoproteins","volume":"347","author":"Kraus","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcma.2014.11.005","article-title":"2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension","volume":"78","author":"Chiang","year":"2015","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jfma.2016.11.013_bib25","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/bmj.319.7224.1523","article-title":"Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors","volume":"319","author":"Rimm","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2016.11.013_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0021-9150(84)90193-X","article-title":"Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis. A control clinical trial","volume":"53","author":"Rabkin","year":"1984","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.atherosclerosis.2009.07.024","article-title":"Effects of smoking cessation and weight gain on cardiovascular disease risk factors in Asian male population","volume":"208","author":"Yoon","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archinte.166.3.285","article-title":"Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials","volume":"166","author":"Nordmann","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib29","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1172\/JCI37385","article-title":"Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight\/obese humans","volume":"119","author":"Stanhope","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jfma.2016.11.013_bib30","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/ajcn\/72.5.1128","article-title":"Effects of dietary fructose on plasma lipids in healthy subjects","volume":"72","author":"Bantle","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jfma.2016.11.013_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2008.03.092","article-title":"Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis","volume":"136","author":"Eslick","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ejcn.2011.64","article-title":"Effects of cocoa products\/dark chocolate on serum lipids: a meta-analysis","volume":"65","author":"Tokede","year":"2011","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jfma.2016.11.013_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2015.04.004","article-title":"Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain \u2014 a systematic review and meta-analysis","volume":"240","author":"Gerards","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib34","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/CIRCULATIONAHA.106.171052","article-title":"Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee","volume":"113","author":"Sacks","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib35","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2016.11.013_bib36","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2016.11.013_bib37","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib38","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib39","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib40","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib41","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib42","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib44","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1001\/jama.1990.03450230049028","article-title":"Beneficial effects of colestipol\u2013niacin on coronary atherosclerosis: a 4-year follow-up","volume":"264","author":"Cashin-Hemphill","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2016.11.013_bib45","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib46","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"The HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib48","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","article-title":"The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression","volume":"61","author":"Lavigne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib49","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib50","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","author":"Bezafibrate Infarction Prevention (BIP) Study","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib52","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib53","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib54","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jfma.2016.11.013_bib56","article-title":"A randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ethyl-ester omega-3 fatty acid in Taiwanese hypertriglyceridemic patients","author":"Su","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jfma.2016.11.013_bib57","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib58","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib59","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2016.11.013_bib60","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib61","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2016.11.013_bib62","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/01.CIR.0000140261.58966.A4","article-title":"Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study","volume":"110","author":"Okazaki","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib63","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.atherosclerosis.2009.12.001","article-title":"Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study","volume":"210","author":"Dohi","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib64","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.amjcard.2007.04.023","article-title":"Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein > or =100 mg\/dl versus <100 mg\/dl","volume":"100","author":"Spencer","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib65","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.jacc.2011.05.057","article-title":"Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol","volume":"58","author":"Lee","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib66","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib67","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.atherosclerosis.2013.12.003","article-title":"The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial","volume":"233","author":"Zhao","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib68","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib69","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.atherosclerosis.2016.05.025","article-title":"Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE-IVUS trial","volume":"251","author":"Tsujita","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib70","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2010.02.026","article-title":"Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome","volume":"55","author":"Nicholls","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib71","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1536\/ihj.48.677","article-title":"Effect of early versus late in-hospital initiation of statin therapy on the clinical outcomes of patients with acute coronary syndrome","volume":"48","author":"Li","year":"2007","journal-title":"Int Heart J"},{"key":"10.1016\/j.jfma.2016.11.013_bib72","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.amjcard.2004.07.085","article-title":"Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times","volume":"94","author":"Saab","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib73","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","article-title":"Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"113","author":"Navarese","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib74","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib75","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib76","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib77","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2016.11.013_bib78","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib79","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib80","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib82","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib83","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2015.01.036","article-title":"Impact of statins on serial coronary calcification during atheroma progression and regression","volume":"65","author":"Puri","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib84","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1253\/circj.CJ-09-0358","article-title":"Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)","volume":"73","author":"Takayama","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.jfma.2016.11.013_bib85","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.amjcard.2012.01.399","article-title":"Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial)","volume":"109","author":"Lee","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib86","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2261-14-60","article-title":"Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound","volume":"14","author":"Gao","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jfma.2016.11.013_bib87","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2007.03.102","article-title":"Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)","volume":"100","author":"LaRosa","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib88","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)","volume":"97","author":"Pedersen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib89","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib90","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.hrtlng.2009.07.004","article-title":"Coronary artery disease in patients with peripheral artery disease","volume":"39","author":"Duran","year":"2010","journal-title":"Heart Lung"},{"key":"10.1016\/j.jfma.2016.11.013_bib91","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13063-016-1237-0","article-title":"Impact of routine coronary catheterization in low extremity artery disease undergoing percutaneous transluminal angioplasty: study protocol for a multi-center randomized controlled trial","volume":"17","author":"Chen","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.jfma.2016.11.013_bib92","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jfma.2016.11.013_bib93","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9149(97)00904-1","article-title":"Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)","volume":"81","author":"Pedersen","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib94","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(03)00010-X","article-title":"Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease","volume":"114","author":"Mondillo","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib95","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0002-9149(03)00833-6","article-title":"Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at 6 months and one year after treatment","volume":"92","author":"Aronow","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib96","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib97","first-page":"CD000123","article-title":"Lipid-lowering for peripheral arterial disease of the lower limb","volume":"4","author":"Aung","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfma.2016.11.013_bib98","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: randomised controlled trial","volume":"325","author":"Meade","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2016.11.013_bib99","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","article-title":"The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline","volume":"218","author":"West","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/ije\/dyg106","article-title":"Cholesterol, coronary heart disease, and stroke in the Asia Pacific region","volume":"32","author":"Zhang","year":"2003","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib101","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1161\/STROKEAHA.115.011164","article-title":"Lipids and cerebrovascular disease: research and practice","volume":"46","author":"Yaghi","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.jfma.2016.11.013_bib102","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib103","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/01.WNL.0000144282.42222.DA","article-title":"Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups","volume":"63","author":"Tirschwell","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2016.11.013_bib104","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1161\/STROKEAHA.108.529537","article-title":"LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study","volume":"40","author":"Imamura","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.jfma.2016.11.013_bib105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.atherosclerosis.2012.01.013","article-title":"High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population: the JPHC study","volume":"221","author":"Cui","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib106","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM198904063201405","article-title":"Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial","volume":"320","author":"Iso","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib107","doi-asserted-by":"crossref","first-page":"e001974","DOI":"10.1161\/JAHA.112.001974","article-title":"Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65,594 individuals from 10 cohort studies in Japan","volume":"1","author":"Nagasawa","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jfma.2016.11.013_bib108","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1161\/STROKEAHA.113.001326","article-title":"Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis","volume":"44","author":"Wang","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.jfma.2016.11.013_bib109","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2016.11.013_bib110","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1210\/jc.2016-1831","article-title":"Ezetimibe\u2013simvastatin therapy reduce recurrent ischemic stroke risks in type 2 diabetic patients","volume":"101","author":"Liu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2016.11.013_bib111","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib112","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/STROKEAHA.108.534107","article-title":"Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes","volume":"40","author":"Amarenco","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.jfma.2016.11.013_bib113","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1212\/01.wnl.0000296277.63350.77","article-title":"Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study","volume":"70","author":"Goldstein","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2016.11.013_bib114","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.112.655894","article-title":"Statin therapy and the risk of intracerebral hemorrhage \u2014 a meta-analysis of 31 randomized controlled trials","volume":"43","author":"McKinney","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.jfma.2016.11.013_bib115","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1161\/CIRCULATIONAHA.114.013046","article-title":"Risk of intracranial hemorrhage from statin use in Asians: a nationwide cohort study","volume":"131","author":"Chang","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib116","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jfma.2016.11.013_bib117","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/STROKEAHA.112.668277","article-title":"Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials","volume":"44","author":"N\u00ed Chr\u00f3in\u00edn","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.jfma.2016.11.013_bib118","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5853\/jos.2015.17.3.282","article-title":"Statins in acute ischemic stroke: a systematic review","volume":"17","author":"Hong","year":"2015","journal-title":"J Stroke"},{"key":"10.1016\/j.jfma.2016.11.013_bib119","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e318270400b","article-title":"Outcomes after thrombolysis in AIS according to prior statin use: a registry and review","volume":"79","author":"Meseguer","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2016.11.013_bib120","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.115.016183","article-title":"Clinical effectiveness of statin therapy after ischemic stroke: primary results from the statin therapeutic area of the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study","volume":"132","author":"O'Brien","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib121","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.amjcard.2009.07.065","article-title":"Effect of in-hospital initiation of lipid-lowering therapy on six-month outcomes in patients with acute ischemic stroke or transient ischemic attack","volume":"105","author":"Yeh","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib122","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jfma.2013.10.007","article-title":"Guideline-adherent therapy in patients with cardiovascular diseases in Taiwan","volume":"114","author":"Jeng","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2016.11.013_bib123","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ijs.12624","article-title":"Statin use in spontaneous intracerebral hemorrhage: a systematic review and meta-analysis","volume":"10","author":"Jung","year":"2015","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jfma.2016.11.013_bib124","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/ene.12649","article-title":"Early statin therapy in patients with acute intracerebral hemorrhage without prior statin use","volume":"22","author":"Chen","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jfma.2016.11.013_bib125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2010.02.011","article-title":"Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis","volume":"212","author":"Labreuche","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib126","first-page":"CD009580","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","volume":"10","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfma.2016.11.013_bib127","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2016.11.013_bib128","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jvs.2013.06.085","article-title":"Best evidence for medical therapy for carotid artery stenosis","volume":"58","author":"Constantinou","year":"2013","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jfma.2016.11.013_bib129","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5551\/jat.14001","article-title":"Effect of statin therapy on the progression of common carotid artery intima-media thickness: an updated systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Huang","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jfma.2016.11.013_bib130","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ejvs.2015.06.115","article-title":"Long-term mortality in patients with asymptomatic carotid stenosis: implications for statin therapy","volume":"50","author":"Giannopoulos","year":"2015","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jfma.2016.11.013_bib131","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijcard.2013.01.198","article-title":"Treatment with statins improves long-term survival in individuals with carotid artery stenosis","volume":"168","author":"W\u00f6rlund","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib132","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1161\/STROKEAHA.108.516450","article-title":"Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial","volume":"39","author":"Sillesen","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.jfma.2016.11.013_bib133","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1586\/erc.10.129","article-title":"Epidemiology, diagnosis and management of intracranial atherosclerotic disease","volume":"8","author":"Jeng","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jfma.2016.11.013_bib134","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0140-6736(13)61088-0","article-title":"Intracranial atherosclerosis","volume":"383","author":"Qureshi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib135","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa043033","article-title":"Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis","volume":"352","author":"Chimowitz","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib136","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1212\/01.wnl.0000279338.18776.26","article-title":"Risk factor status and vascular events in patients with symptomatic intracranial stenosis","volume":"69","author":"Chaturvedi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2016.11.013_bib137","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000215939","article-title":"Statins for asymptomatic middle cerebral artery stenosis: the regression of cerebral artery stenosis study","volume":"28","author":"Mok","year":"2009","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jfma.2016.11.013_bib138","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00415-009-0960-9","article-title":"Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis","volume":"256","author":"Tan","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.jfma.2016.11.013_bib139","first-page":"605","article-title":"Predictors of symptomatic and symptomatic intracranial atherosclerosis: what is different and why?","volume":"21","author":"Kim","year":"2014","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jfma.2016.11.013_bib140","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1105335","article-title":"Stenting versus aggressive medical therapy for intracranial arterial stenosis","volume":"365","author":"Chimowitz","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib141","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(13)62038-3","article-title":"Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial","volume":"383","author":"Derdeyn","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib142","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/jamaneurol.2015.4315","article-title":"Factors associated with recurrent ischemic stroke in the medical group of the SAMMPRIS trial","volume":"73","author":"Waters","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jfma.2016.11.013_bib143","first-page":"S1","article-title":"Standards of medical care in diabetes\u20142016","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2016.11.013_bib144","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2337\/diacare.20.7.1183","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","volume":"20","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2016.11.013_bib145","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/bmj.308.6940.1323","article-title":"Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes","volume":"308","author":"McCance","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2016.11.013_bib146","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2337\/diacare.20.5.785","article-title":"Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited","volume":"20","author":"Engelgau","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2016.11.013_bib147","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1001\/archinte.164.19.2147","article-title":"Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies","volume":"164","author":"Levitan","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib148","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.2337\/diacare.28.11.2756","article-title":"Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan","volume":"28","author":"Wen","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2016.11.013_bib149","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1475-2840-10-56","article-title":"A progressive increase in cardiovascular risk assessed by coronary angiography in non-diabetic patients at sub-diabetic glucose levels","volume":"10","author":"Schinner","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jfma.2016.11.013_bib150","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib151","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJM200005113421903","article-title":"Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus","volume":"342","author":"Chandalia","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib152","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/01.CIR.0000062644.42133.5F","article-title":"Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women","volume":"107","author":"Hu","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib153","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1161\/CIRCULATIONAHA.110.968735","article-title":"Components of a cardioprotective diet: new insights","volume":"123","author":"Mozaffarian","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib154","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.puhe.2007.02.014","article-title":"Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials","volume":"121","author":"Kelley","year":"2007","journal-title":"Public Health"},{"key":"10.1016\/j.jfma.2016.11.013_bib155","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2337\/diacare.28.4.799","article-title":"Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes","volume":"28","author":"Hu","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2016.11.013_bib156","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Cholesterol Treatment Trialists' (CTT) Collaborators","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib157","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.amjcard.2013.10.043","article-title":"Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy","volume":"113","author":"Wang","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib158","doi-asserted-by":"crossref","first-page":"e76298","DOI":"10.1371\/journal.pone.0076298","article-title":"Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study)","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2016.11.013_bib159","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.amjcard.2014.12.009","article-title":"Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus","volume":"115","author":"Lai","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2015.04.121","article-title":"Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: a population-based dynamic cohort study","volume":"190","author":"Chang","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib161","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1210\/jc.2004-0820","article-title":"Non-HDL cholesterol level is reliable to be an early predictor for vascular inflammation in type 2 diabetes mellitus","volume":"9","author":"Wang","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2016.11.013_bib162","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijcard.2005.07.021","article-title":"Independent association between triglycerides and coronary artery disease in Taiwanese type 2 diabetic patients","volume":"111","author":"Tseng","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib163","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.annepidem.2005.01.005","article-title":"A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region","volume":"15","author":"Barzi","year":"2005","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib164","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(08)60952-6","article-title":"All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan","volume":"371","author":"Wen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib165","doi-asserted-by":"crossref","unstructured":"Hung TC, Su CH, Wu YJ, Hung CL, Yeh HI, Wang LY. Cardiovascular risk and lipid management reimbursement between patients with stage 3\u20135 chronic kidney disease and those with diabetes mellitus. Int J Gerontol. http:\/\/dx.doi.org\/10.1016\/j.ijge.2016.08.001.","DOI":"10.1016\/j.ijge.2016.08.001"},{"key":"10.1016\/j.jfma.2016.11.013_bib166","doi-asserted-by":"crossref","first-page":"e99645","DOI":"10.1371\/journal.pone.0099645","article-title":"Modification of diet in renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI) equations for Taiwanese adults","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2016.11.013_bib167","doi-asserted-by":"crossref","first-page":"785","DOI":"10.7326\/0003-4819-156-11-201203200-00391","article-title":"Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review","volume":"156","author":"Earley","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib168","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.jacc.2008.03.025","article-title":"Managing dyslipidemia in chronic kidney disease","volume":"51","author":"Harper","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib169","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7150\/ijms.7069","article-title":"The impact of chronic kidney disease on lipid management and goal attainment in patients with atherosclerosis diseases in Taiwan","volume":"11","author":"Lin","year":"2014","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jfma.2016.11.013_bib170","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1681\/ASN.2005121320","article-title":"Lipids and renal disease","volume":"17","author":"Trevisan","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2016.11.013_bib171","doi-asserted-by":"crossref","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib172","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.291.7.844","article-title":"Predictors of new-onset kidney disease in a community-based population","volume":"291","author":"Fox","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2016.11.013_bib173","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1681\/ASN.V1482084","article-title":"Cholesterol and the risk of renal dysfunction in apparently healthy men","volume":"14","author":"Schaeffner","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2016.11.013_bib174","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.ki.5002017","article-title":"Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study","volume":"71","author":"Yamagata","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2016.11.013_bib175","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.ajkd.2006.10.007","article-title":"Epidemiological features of CKD in Taiwan","volume":"49","author":"Kuo","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2016.11.013_bib176","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1046\/j.1523-1755.1999.07112.x","article-title":"Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury","volume":"71","author":"Hattori","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jfma.2016.11.013_bib177","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ki.1997.260","article-title":"Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study","volume":"51","author":"Hunsicker","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2016.11.013_bib178","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.09320913","article-title":"Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study","volume":"9","author":"Rahman","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2016.11.013_bib179","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1681\/ASN.2012080870","article-title":"Association between LDL-C and risk of myocardial infarction in CKD","volume":"24","author":"Tonelli","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2016.11.013_bib180","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.2215\/CJN.01450210","article-title":"Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease","volume":"5","author":"Chawla","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2016.11.013_bib181","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2016.11.013_bib182","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2014.10.005","article-title":"KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD","volume":"65","author":"Sarnak","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2016.11.013_bib183","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib184","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib186","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","author":"National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","journal-title":"Circulation"},{"issue":"I\u2013IV","key":"10.1016\/j.jfma.2016.11.013_bib187","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease","volume":"41","author":"Kidney Disease Outcomes Quality Initiative (K\/DOQI) Group","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2016.11.013_bib188","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib189","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib190","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.ajkd.2006.12.005","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","author":"KDOQI","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2016.11.013_bib191","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"54","author":"Colhoun","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2016.11.013_bib192","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib193","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MNH.0b013e3283435f0e","article-title":"Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease","volume":"20","author":"Navaneethan","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jfma.2016.11.013_bib194","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib195","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2016.11.013_bib196","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/eurheartj\/eht065","article-title":"Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"34","author":"Hou","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2016.11.013_bib197","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib198","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jacl.2016.01.009","article-title":"Genetic diagnosis of familial hypercholesterolemia in Han Chinese","volume":"10","author":"Chiou","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jfma.2016.11.013_bib199","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","article-title":"Familial hypercholesterolemia\u2014epidemiology, diagnosis, and screening","volume":"17","author":"Singh","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jfma.2016.11.013_bib200","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cjca.2014.09.028","article-title":"Canadian Cardiovascular Society position statement on familial hypercholesterolemia","volume":"30","author":"Genest","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jfma.2016.11.013_bib201","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2016.11.013_bib202","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib203","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2016.11.013_bib204","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.ATV.9.2.211","article-title":"Homozygous familial hypercholesterolemia among French Canadians in Quebec Province","volume":"9","author":"Moorjani","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jfma.2016.11.013_bib205","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.281.6241.633","article-title":"A host of hypercholesterolaemic homozygotes in South Africa","volume":"281","author":"Seftel","year":"1980","journal-title":"Br Med J"},{"key":"10.1016\/j.jfma.2016.11.013_bib206","first-page":"1133","article-title":"A novel mutation in proprotein convertase subtilisin\/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family","volume":"123","author":"Lin","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jfma.2016.11.013_bib207","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1586\/erc.13.7","article-title":"Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes","volume":"11","author":"Alonso","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jfma.2016.11.013_bib208","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.atherosclerosissup.2014.07.004","article-title":"Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement","volume":"15","author":"Bruckert","year":"2014","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jfma.2016.11.013_bib209","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/15748901112079990001","article-title":"Novel therapeutic strategies for the homozygous familial hypercholesterolemia","volume":"8","author":"Mombelli","year":"2013","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"10.1016\/j.jfma.2016.11.013_bib210","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1517\/14656566.2010.512006","article-title":"Mipomersen as a potential adjunctive therapy for hypercholesterolemia","volume":"11","author":"Patel","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jfma.2016.11.013_bib211","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib212","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/clp.14.43","article-title":"The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia","volume":"9","author":"McGowan","year":"2014","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.jfma.2016.11.013_bib213","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40256-013-0030-7","article-title":"Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia","volume":"13","author":"Perry","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jfma.2016.11.013_bib214","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(12)61845-5","article-title":"Lomitapide for homozygous familial hypercholesterolaemia","volume":"381","author":"Raal","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib215","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib216","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40267-013-0087-z","article-title":"Lomitapide: a guide to its use in adults with homozygous familial hypercholesterolaemia in the EU","volume":"29","author":"Lyseng-Willliamson","year":"2013","journal-title":"Drugs Ther Perspect"},{"key":"10.1016\/j.jfma.2016.11.013_bib217","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.013_bib218","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J Clin Lipid"},{"key":"10.1016\/j.jfma.2016.11.013_bib219","doi-asserted-by":"crossref","first-page":"A10818","DOI":"10.1161\/circ.132.suppl_3.10818","article-title":"Lomitapide Observational Worldwide Evaluation Registry (LOWER): one-year data [Abstract]","volume":"132","author":"Blom","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2016.11.013_bib220","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1016\/j.jfma.2018.07.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000}}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664616304302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664616304302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T17:53:16Z","timestamp":1719078796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664616304302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":220,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0929664616304302"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2016.11.013","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jfma.2018.07.007","asserted-by":"object"}]},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2017 Taiwan lipid guidelines for high risk patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2016.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}